HYG vs IBB

iShares iBoxx High Yield Corporate Bond ETF vs iShares Biotechnology ETF

Quick take
  • • IBB has the lower expense ratio at 0.44% vs 0.49% for HYG.
  • • HYG pays a higher dividend yield (6.09%).

Side-by-side metrics

MetricHYGIBB
Expense ratio
Annual fee. Lower is better.
0.49%0.44%
Dividend yield
Trailing 12-month yield.
6.09%0.16%
AUM
Assets under management — bigger funds are typically more liquid.
$17.71B$11.50B
YTD return
1.01%30.22%
1-year return
——
3-year return
Annualized.
——
5-year return
Annualized.
——
10-year return
Annualized.
——
Beta (3Y)
Volatility relative to the market. Closer to 1 = market-like.
0.650.60
P/E ratio
—25.48
Last price
$77.36$217.75
Inception
——
Issuer
iSharesiShares

HYG top holdings

Top holdings · HYG
XTSLABlackRock Cash Funds Treasury SL Agency1.06%
Sector breakdown · HYG
Real Estate0.4%
Utilities99.6%

IBB top holdings

Top holdings · IBB
GILDGilead Sciences Inc8.94%
AMGNAmgen Inc8.31%
VRTXVertex Pharmaceuticals Inc7.87%
REGNRegeneron Pharmaceuticals Inc6.24%
MRNAModerna Inc5.49%
NTRANatera Inc3.78%
ARGXargenx SE ADR3.36%
BIIBBiogen Inc2.52%
RVMDRevolution Medicines Inc Ordinary Shares2.50%
ILMNIllumina Inc2.41%
Sector breakdown · IBB
Healthcare100.0%

About HYG

HYG (iShares iBoxx High Yield Corporate Bond ETF) is US high-yield corporate bonds. Managed by iShares, the fund carries $17.7B in assets under management, an expense ratio of 0.49%, a dividend yield of 6.09%. Its largest holding is BlackRock Cash Funds Treasury SL Agency (XTSLA), which represents 1.1% of the portfolio. Real Estate is the fund's largest sector exposure at 0.4%.

About IBB

IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.